SCHEMBL2645356

SCHEMBL2645356

CS(=O)(=O)c1ccc(Oc2cc([N+](=O)[O-])c(NC(=O)c3cnccn3)c(F)c2F)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
POLB P06746 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
LMNA P02545 1/20 0.44
ALDH1A1 P00352 2/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
TP53 P04637 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.39
TSHR P16473 1/20 0.39
GLA P06280 1/20 0.38
PYGL P06737 1/20 0.38
PYGM P11217 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
USP2 O75604 1/20 0.37
HTT P42858 1/20 0.37
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1657406 0.74 MAPT (0.42) MAPTPOLBMEN1KMT2ALMNA
SCHEMBL2645604 0.74 MAPT (0.41) MAPTLMNAALDH1A1KDM4EHTT
SCHEMBL2646046 0.71 NR1H2 (0.38) MAPTLMNAALDH1A1SMN1; SMN2HTT
SCHEMBL2646047 0.70 MAPT (0.39) MAPTPOLBMEN1KMT2ALMNA
SCHEMBL6705932 0.68 NPC1 (0.61) MAPTPOLBMEN1KMT2ALMNA
SCHEMBL1455288 0.66 MAPT (0.76) MAPTPOLBMEN1KMT2ALMNA
SCHEMBL564681 0.65 MAPT (0.43) MAPTPOLBMEN1KMT2ALMNA
SCHEMBL1038407 0.64 MEN1 (0.41) MAPTPOLBMEN1KMT2AALDH1A1
SCHEMBL2646559 0.63 FFAR1 (0.43)
SCHEMBL1656304 0.63 MAPT (0.50) MAPTPOLBMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 EP disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 US disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 MAPT 3676/4885POLB 3730/4885MEN1 4085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.